Biosignal

BEACON BIOSIGNALS EXPANDS SLEEP ANALYSIS CAPABILITIES WITH FDA CLEARANCE OF SLEEPSTAGEML

Retrieved on: 
Wednesday, March 27, 2024
Diagnosis, Neurology, EEG, Guilloché, Sleep, Harvard Medical School, DSM-IV codes, Machine learning, Psychiatry, Algorithm, Interest, Patient, PSG, Research, Beacon, Neuroscience, Doctor of Philosophy, Biosignal, Clinical trial, PCCP, Literature, FDA, Neurodegenerative disease, Pharmaceutical industry

BOSTON, March 27, 2024 /PRNewswire/ -- Beacon Biosignals announced today that it has received FDA 510(k) clearance for SleepStageML™️, an advanced machine learning software that automatically stages sleep from electroencephalogram (EEG) signals of clinical polysomnography (PSG) recordings to aid in the diagnosis and evaluation of sleep and sleep-related disorders. Beacon Biosignals is a health technology company focused on accelerating the development of therapies for neurological, psychiatric, and sleep disorders, and SleepStageML opens the door for more consistent, efficient, and precise sleep staging for these therapeutic areas. This latest clearance complements Beacon's previous FDA clearance of the Dreem 3S wearable headband and integrated algorithms, providing a comprehensive solution for precisely measuring sleep architecture across home and clinical settings.

Key Points: 
  • Beacon Biosignals is a health technology company focused on accelerating the development of therapies for neurological, psychiatric, and sleep disorders, and SleepStageML opens the door for more consistent, efficient, and precise sleep staging for these therapeutic areas.
  • This latest clearance complements Beacon's previous FDA clearance of the Dreem 3S wearable headband and integrated algorithms, providing a comprehensive solution for precisely measuring sleep architecture across home and clinical settings.
  • "With FDA clearances for both SleepStageML and Dreem 3S™ headband, Beacon now provides an unparalleled capability to measure sleep physiology whether studies are conducted in-home or in-clinic," said Jacob Donoghue, MD, PhD, CEO of Beacon Biosignals.
  • This FDA clearance represents a major milestone that bolsters Beacon Biosignals' powerful machine learning platform for rapidly analyzing large neurophysiology datasets.

Beacon Biosignals welcomes David Matthews, PhD, as Chief Business Officer

Retrieved on: 
Thursday, February 1, 2024
Sleep, Intelligence, Molecular biology, Software, Growth, MD, Boston Consulting Group, NIH, Therapy, Neuroscience, Machine learning, Patient, Biological engineering, Biosignal, Disease, Brain, Partner, Medicine, NSF, Medical device, EEG, Doctor of Philosophy, Princeton University, BCG, University, Health

BOSTON, Feb. 1, 2024 /PRNewswire/ -- Beacon Biosignals, a leading computational neurodiagnostics and EEG analytics company, has appointed David Matthews, PhD, as Chief Business Officer to oversee commercial and strategic activities.

Key Points: 
  • Beacon Biosignals partners with top biopharma companies to better understand brain health using clinical-grade EEG and AI-powered analysis.
  • The company's Dreem 3S wearable medical device enables validated sleep endpoints at-home and unlocks a scale of brain activity data never before available.
  • Dr. Matthews will draw on his deep expertise in healthcare strategy, commercial development, and computational neuroscience to create new partnerships, expand relationships, and drive continued innovation for Beacon Biosignals through the company's next phase of growth.
  • "We are thrilled to welcome David to our leadership team," said Jacob Donoghue, MD PhD, CEO of Beacon Biosignals.

World first: Multiomics biosignal detection in real-time via an electronic biosensor

Retrieved on: 
Tuesday, June 13, 2023
Learning, DNA, Omicron, Biosignal, Electronics, COVID-19, Paragraf Lex, COVID, RNA, DARPA, Pandemic, SAN, Viral, Research, BPU, PCR, Georgia Tech Research Institute, Vaccine, US ARMY

Novel multiomics methodology enables detection of both protein and RNA or DNA biosignals simultaneously.

Key Points: 
  • Novel multiomics methodology enables detection of both protein and RNA or DNA biosignals simultaneously.
  • This scientific breakthrough was recently published as a cover story in Advanced Materials Technology , marking the first public demonstration of this novel methodology for multiomics.
  • The outcome of this multiomics project represents the first generation of a novel multiomics platform that – with comparable accuracy and specificity – can drive a new level of point of care disease detection.
  • Paragraf's novel multiomics methodology is based on their BPU (Biosignal Processing Unit) platform and is currently available for Research Use Only.

Dr. Kiana Aran makes Inc.'s 2023 Female Founders list

Retrieved on: 
Tuesday, April 4, 2023
CRISPR, Food, Female, Therapy, Biosignal, Medical diagnosis, Woman, Keck Graduate Institute, KGI, Associate, Bangladesh Technical Education Board, Rutgers University, Organization, Scientist, Patient, Rihanna, SNP, SAN, Pleasure, Shoe, BPU, NIH, Pharmaceutical industry, Science

SAN DIEGO, April 4, 2023 /PRNewswire/ -- Inc. today announced its sixth annual Female Founders list, honoring a bold group of 200 women whose innovations and ideas are shaping the world into a better place.

Key Points: 
  • SAN DIEGO, April 4, 2023 /PRNewswire/ -- Inc. today announced its sixth annual Female Founders list, honoring a bold group of 200 women whose innovations and ideas are shaping the world into a better place.
  • Winner of the 2021 Nature Award for Inspiring Women in Science, Dr. Kiana Aran, makes Inc.’s 2023 Female Founders list.
  • Being recognized as a top female founder motivates me to continue pushing the boundaries of science and technology."
  • "These 200 female founders have identified solutions to difficult problems and created valuable, industry-changing companies out of them.

Previously unachievable drug discovery insights created by Cardea's BPU platform

Retrieved on: 
Tuesday, January 10, 2023
Bar-Ilan University, Partnership, Peptide, Protein, Drug discovery, Research, BPU, SAN, Pharmacology, Biology, Attention, Stanford University, Journal of Visualized Experiments, Biosignal, Chemistry, ITC, Doctor of Philosophy, Biochemistry, Pharmaceutical industry, Fine chemical

SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Today, Cardea Bio, Inc. reaches an 8-year milestone of the first external partner starting to use the BPU (Biosignal Processing Unit) platform for advancing drug discovery research to produce new and highly sought-after insights.

Key Points: 
  • SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Today, Cardea Bio, Inc. reaches an 8-year milestone of the first external partner starting to use the BPU (Biosignal Processing Unit) platform for advancing drug discovery research to produce new and highly sought-after insights.
  • In my estimation, the BPU platform is a very important tool for drug discovery, because it's fast, easy to use, and doesn't require a lot of reagents.
  • This exemplifies how the BPU should be an important part of the toolbox in drug discovery and a technology that all pharma companies can benefit from."
  • With Cardea, I believe the possibilities to solve some of the largest problems in drug discovery are achievable.

Graphene for electronics making strides towards ISO standards - spearheaded by MITO and Cardea

Retrieved on: 
Tuesday, December 20, 2022
ANSI, National Physical Laboratory (United Kingdom), Nature, TAG, Language, National Institute of Standards and Technology, SAN, International Organization for Standardization, Working group, Biotechnology, Health, Graphene, Sensation, EPA, IP, TC, ISCB Senior Scientist Award, NIST, FDA, Nanotechnology, Goldsmith, Biosignal, Core Component Technical Specification, Lead, Agriculture, Technical, National Physical Laboratory, American National Standards Institute, Classification, Multimedia, Environmental monitoring, BPU, Doctor of Philosophy, National Immunization Technical Advisory Group, Electronics, Technical standard, ISO, Medical device, Biology, Cardea

"We see a bright future for diagnostic tools based on graphene electronics, but we're not waiting for that future - we're making it happen!

Key Points: 
  • "We see a bright future for diagnostic tools based on graphene electronics, but we're not waiting for that future - we're making it happen!
  • On the graphene Technical Specification team, that expertise came from Dr. Angela Hight Walker, a Senior Scientist at NIST.
  • Dr. Hight Walker states, "Graphene will play a major role in multiple industries; developing documentary standards will certainly hasten the pace.
  • Having US companies like MITO Materials and Cardea spearhead standards discussions indicates a new threshold of maturity for the U.S.-based graphene industry."

ABR Time Series Processor (TSP) AI Chip Named CES 2023 INNOVATION AWARDS HONOREE

Retrieved on: 
Monday, November 21, 2022
Engineering, LMU, Clothing, AI, Intelligence, Biosignal, Consumer Electronics Show, Language, TSP, CES, Speech, Innovation, CTA, Completeness, Consumer Technology Association, ABR, TSP (econometrics software), Medical device

WATERLOO, Ontario, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Applied Brain Research Inc. (ABR) today announced that it has been named a CES 2023 Innovation Awards Honoree for the ABR Time Series Processor (TSP) AI chip .

Key Points: 
  • WATERLOO, Ontario, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Applied Brain Research Inc. (ABR) today announced that it has been named a CES 2023 Innovation Awards Honoree for the ABR Time Series Processor (TSP) AI chip .
  • This year's Consumer Electronics Show (CES) Innovation Awards program received a record-high number of over 2,100 submissions.
  • The announcement was made ahead of CES 2023, the world's most influential technology event, happening January 5th to 8th, 2023 in Las Vegas, NV.
  • "We are honored to have Applied Brain Research's TSP be selected as a CES 2023 Innovation Awards honoree," stated Peter Suma, co-CEO of ABR.

Semiconductor Research Corporation invites Cardea to be part of defining how to integrate biology with electronics

Retrieved on: 
Thursday, August 25, 2022
CHIPS, Kepler, Nature, NXP, Nanotechnology, SkyWater Technology, AMAT, Workforce, University, CEO, Binghamton University, Purdue University, Intel, Rochester Institute of Technology, Research, National Institute, Agriculture, Micrometre, Traction, NIST, Semiconductor Research Corporation, Doctor of Philosophy, Internet, Sandia National Laboratories, SAN, Environmental monitoring, SRC, Publishing, MAPT, SK, ADI, University of Florida, Student, Power, Ministry of Education (Malaysia), GF, National Institute of Standards and Technology, Leadership, Biotechnology, BPU, IP, AMD, Morgan State University, Congress, Pacific Northwest National Laboratory, Growth, IBM, Clarkson University, Government, Health, Biosignal, Electronics, TWG, SUNY Polytechnic Institute, Mobile phone, Technology, Biology, Qualcomm

SRC President and CEO, Dr. Todd Younkin , states, "With Cardea, we're seeing a commercial electronics company that are truly the pioneers in biocompatible semiconductors.

Key Points: 
  • SRC President and CEO, Dr. Todd Younkin , states, "With Cardea, we're seeing a commercial electronics company that are truly the pioneers in biocompatible semiconductors.
  • The electronics community, as a whole, will benefit greatly from Cardea sharing their experiences, so we're really excited to have them on board in this project."
  • "Early in my career when I interacted with the electronics community, nanotechnology was seen as something interesting but academic.
  • And now being invited to being part of setting the standards for both graphene in electronics and connecting semiconductors with biology.

ISO standards for the use of graphene in electronics spearheaded by the Graphene Council and Cardea Bio

Retrieved on: 
Thursday, August 18, 2022
Graphene, Interview, Electronics, Industry, IEC, Technology, IP, Agriculture, Nature, Environmental monitoring, Biosignal, SAN, CVD, Biotechnology, Chemical vapor deposition, Doctor of Philosophy, BPU, Philosophy, Medicine, Health, Medical device, Carbon fibers, Biology

Specifically, what should the standards be around an electronics grade mono-layer CVD (Chemical Vapor Deposition) graphene?"

Key Points: 
  • Specifically, what should the standards be around an electronics grade mono-layer CVD (Chemical Vapor Deposition) graphene?"
  • Standards are important for that and what the Graphene Council is doing, is important for that."
  • The Graphene Council is a member of the ISO/ANSI TC 229 Nanotechnology Standards Development Group and the IEC TC 113, Nano-Electrotechnologies Technical Committee .
  • Executive Director at the Graphene Council, Terrance Barkan , adds "On the standards side, Cardea has been a huge help for us in understanding the needs for this particular type of graphene for electronics.

Exponential growth in production demand sees Cardea eyeing the millionth biosensor in 2023

Retrieved on: 
Tuesday, August 16, 2022
Multimedia, Electronics, Industry, Silicon, European Innovation Council, Technology, IP, Agriculture, Nature, Environmental monitoring, Biosignal, SAN, McKinsey & Company, Biotechnology, Doctor of Philosophy, CTO, Salt, MEMS, BPU, IEEE Medal for Environmental and Safety Technologies, Semiconductor, Time, Health, Consumer electronics, Mobile phone, Fine chemical, Cardea, Biology

This is what we've done at Cardea in creating our BPU platform of wetware, nanoware, hardware, and software modules.

Key Points: 
  • This is what we've done at Cardea in creating our BPU platform of wetware, nanoware, hardware, and software modules.
  • While the use of graphene in electronics has been in the experimental phase for years, it's only recently that scalable production has been achieved.
  • Cardea is - both in terms of production capacity and quality, as well as IP - the world's leading company in graphene biosensors.
  • Kelly Huang, PhD, Chief Operating Officer at Cardea, adds , "We've made significant improvements in our production processes over the past year.